189 related articles for article (PubMed ID: 8307502)
21. Treatment, results and prognostic factors in stage I and II sarcomas of the corpus uteri.
Vongtama V; Karlen JR; Piver SM; Tsukada Y; Moore RH
AJR Am J Roentgenol; 1976 Jan; 126(1):139-47. PubMed ID: 175673
[TBL] [Abstract][Full Text] [Related]
22. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
[TBL] [Abstract][Full Text] [Related]
23. Prognostic parameters for survival of patients with malignant mesenchymal tumors of the uterus.
Nola M; Babić D; Ilić J; Marusić M; Uzarević B; Petrovecki M; Sabioncello A; Kovac D; Jukić S
Cancer; 1996 Dec; 78(12):2543-50. PubMed ID: 8952563
[TBL] [Abstract][Full Text] [Related]
24. Flow cytometric analysis of uterine sarcoma: ploidy and S-phase rate as prognostic indicators.
Malmström H; Schmidt H; Persson PG; Carstensen J; Nordenskjöld B; Simonsen E
Gynecol Oncol; 1992 Feb; 44(2):172-7. PubMed ID: 1544595
[TBL] [Abstract][Full Text] [Related]
25. Comparison of current staging systems and a novel staging system for uterine leiomyosarcoma.
Giuntoli RL; Lessard-Anderson CR; Gerardi MA; Kushnir CL; Cliby WA; Metzinger DS; Gostout BS
Int J Gynecol Cancer; 2013 Jun; 23(5):869-76. PubMed ID: 23669444
[TBL] [Abstract][Full Text] [Related]
26. Prognostic factors and treatment outcomes of patients with uterine sarcoma: analysis of 127 patients at a single institution, 1989-2007.
Park JY; Kim DY; Suh DS; Kim JH; Kim YM; Kim YT; Nam JH
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1277-87. PubMed ID: 18506484
[TBL] [Abstract][Full Text] [Related]
27. Flow cytometric analysis of uterine sarcomas.
Lennart K; Lennart B; Ulf S; Bernard T
Gynecol Oncol; 1994 Dec; 55(3 Pt 1):339-42. PubMed ID: 7835771
[TBL] [Abstract][Full Text] [Related]
28. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients.
Abeler VM; Røyne O; Thoresen S; Danielsen HE; Nesland JM; Kristensen GB
Histopathology; 2009 Feb; 54(3):355-64. PubMed ID: 19236512
[TBL] [Abstract][Full Text] [Related]
29. [Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases].
Leung F; Terzibachian JJ; Aouar Z; Govyadovskiy A; Lassabe C
Gynecol Obstet Fertil; 2008 Jun; 36(6):628-35. PubMed ID: 18538624
[TBL] [Abstract][Full Text] [Related]
30. [Histopathological, clinical and prognostic aspects of smooth-muscle tumors of the uterus (cellular myoma, leiomyosarcoma, endometrial stromal sarcoma)].
De Giacomo G; Palla G; Paparatti L; Villani L; Moneta E
Minerva Ginecol; 1988 Feb; 40(2):73-81. PubMed ID: 3399122
[No Abstract] [Full Text] [Related]
31. [Postoperative radiotherapy of uterine sarcoma: a multicentric retrospective study].
Champetier C; Hannoun-Levi JM; Resbeut M; Azria D; Salem N; Tessier E; Ellis S; Cowen D;
Cancer Radiother; 2011 Apr; 15(2):89-96. PubMed ID: 20674447
[TBL] [Abstract][Full Text] [Related]
32. Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer.
Nagai N; Oshita T; Fujii T; Kioka H; Katsube Y; Ohama K
Oncol Rep; 2000; 7(3):551-9. PubMed ID: 10767367
[TBL] [Abstract][Full Text] [Related]
33. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
[TBL] [Abstract][Full Text] [Related]
34. Uterine sarcomas.
Mbatani N; Olawaiye AB; Prat J
Int J Gynaecol Obstet; 2018 Oct; 143 Suppl 2():51-58. PubMed ID: 30306577
[TBL] [Abstract][Full Text] [Related]
35. Sarcomas of the uterus: a clinicopathologic study of 119 patients.
Kahanpää KV; Wahlström T; Gröhn P; Heinonen E; Nieminen U; Widholm O
Obstet Gynecol; 1986 Mar; 67(3):417-24. PubMed ID: 3945454
[TBL] [Abstract][Full Text] [Related]
36. Prognostic importance of vascular endothelial growth factor and its receptors in the uterine sarcoma.
Arita S; Kikkawa F; Kajiyama H; Shibata K; Kawai M; Mizuno K; Nagasaka T; Ino K; Nomura S
Int J Gynecol Cancer; 2005; 15(2):329-36. PubMed ID: 15823121
[TBL] [Abstract][Full Text] [Related]
37. Prognostic factors and outcome in women with uterine sarcoma.
Denschlag D; Masoud I; Stanimir G; Gilbert L
Eur J Surg Oncol; 2007 Feb; 33(1):91-5. PubMed ID: 17174517
[TBL] [Abstract][Full Text] [Related]
38. Uterine sarcoma: prognostic factors and treatment evaluation.
Naaman Y; Shveiky D; Ben-Shachar I; Shushan A; Mejia-Gomez J; Benshushan A
Isr Med Assoc J; 2011 Feb; 13(2):76-9. PubMed ID: 21443030
[TBL] [Abstract][Full Text] [Related]
39. Uterine sarcoma-current management and experience from a regional cancer centre in North India.
Biswas A; Patel F; Kumar P; Srinivasan R; Bera A; Sharma SC; Rajwanshi A
Arch Gynecol Obstet; 2013 Oct; 288(4):873-82. PubMed ID: 23580012
[TBL] [Abstract][Full Text] [Related]
40. Uterine sarcomas: a clinicopathologic study.
Chiara S; Foglia G; Odicino F; Graziani A; Conte PF; Ragni N; Fulcheri E; Pescetto G
Oncology; 1988; 45(6):428-33. PubMed ID: 3186152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
